共 128 条
[11]
Chetoni P.(2001)Herpes simplex virus ocular infections J. Pharm. Sci. 90 288-97
[12]
Rossi S.(2000)Clinical manifestations and treatment considerations of herpes simplex virus infection J. Control Release 63 135-140
[13]
Burgalassi S.(2000)Ocular tolerability and Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 14 379-381
[14]
Monti D.(2008) bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir Int. J. Pharm. 348 175-178
[15]
Mariotti S.(2004)Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption Adv. Drug Deliv. Rev. 56 1437-1452
[16]
Saettone M. F.(1998)An experimental study of a new route for acyclovir administration for anti-keratitis therapeutic treatment Physiol. Rev. 78 969-1054
[17]
Ghosh S.(2003)Effect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit cornea Curr Eye Res 26 151-163
[18]
Jhanji V.(2002)Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development Pharm. Res. 19 1194-1202
[19]
Lamoureux E.(2005)Molecular biology of mammalian plasma membrane amino acid transporters Curr. Drug Targets Immune. Endocr. Metabol. Disord. 5 357-364
[20]
Taylor H. R.(2004)Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea J. Pharmacol. Exp. Ther. 308 1138-1147